Thanks for the attempt. I'd say it is conservative valuation / underestimation.
1. Pills cost less to produce and distribute vs. vaccines (margin much higher vs. vaccines)
2. Sales will be much higher in other countries where vaccination rate is lower vs. Canada, US, etc.
2. EPS / estimation does not reflect future sales from other indications, eg. PAH, CVD, CKD, etc.